Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IGM Biosciences, Inc.IGMS · Entity 76422 | CHIEF FINANCIAL OFFICER | July 23, 2025 | July 25, 2025 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Chief Financial Officer | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IGM Biosciences, Inc.
Report date July 23, 2025 · Filed July 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 170,061 |
Reported balance
After 2025-07-23 transaction · row 1
1 source rowRow 1 · 2025-07-23 · Sale · Disposed 8,741 · Balance 170,061 F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2: This transaction was executed in multiple trades at prices ranging from $1.27 to $1.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
F2: This transaction was executed in multiple trades at prices ranging from $1.27 to $1.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price.
Maze Therapeutics, Inc.
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.61 · Expires 2036-03-01 | Direct | 40,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 40,000 · Balance 40,000 F1: The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-03-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-03-02 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3: The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. F4: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F3: The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.
F4: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 3, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001787359-26-000002 · form4-03032026_090333.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 16:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $45.61 | $0.00 |
DisclosureSEC source: 0001787359-26-000002 · form4-03032026_090333.xml · derivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| September 02, 2025 Filed Sep 2, 2025 18:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $15.32 | $0.00 |
DisclosureSEC source: 0001415889-25-023463 · form4-09022025_100947.xml · derivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2035-09-01 F1 · derivative.exercise_date: The option shall vest as to 1/4th of the total award on September 2, 2026, and thereafter shall vest as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Read SEC document |
| July 23, 2025 Filed Jul 25, 2025 19:06 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 8,741 | $1.27 | $11,125.54 |
DisclosureSEC source: 0001415889-25-020311 · form4-07252025_110759.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,061 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.27 to $1.275. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| June 16, 2025 Filed Jun 20, 2025 20:23 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,522 | $1.20 | $1,825.18 |
DisclosureSEC source: 0001415889-25-017915 · form4-06212025_120658.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,802 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.17 to $1.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 19:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 7,329 | $1.23 | $9,014.67 |
DisclosureSEC source: 0001415889-25-008520 · form4-03182025_110312.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,324 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.19 to $1.28. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 19:10 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,708 | $7.48 | $12,775.84 |
DisclosureSEC source: 0001415889-24-029775 · form4-12192024_121215.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,653 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.00 to $7.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 17:36 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 66,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027363 · form4-11202024_101126.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,361 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 50% of the RSUs shall vest on each of January 12, 2026 and January 11, 2027, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| September 13, 2024 Filed Sep 17, 2024 20:54 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,487 | $11.54 | $17,158.20 |
DisclosureSEC source: 0001415889-24-023586 · form4-09182024_120944.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,694 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $11.20 to $11.795. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $91.50 | Not disclosed |
DisclosureSEC source: 0001415889-24-020004 · form4-07242024_120741.xml · derivative · entry 4 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2031-02-19 F2 · kind: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. F2 · derivative.exercise_date: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Disposition to issuerStock Option (right to buy) · Derivative | 55,000 | Not disclosed Strike: $40.27 | Not disclosed |
DisclosureSEC source: 0001415889-24-020004 · form4-07242024_120741.xml · derivative · entry 3 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,000 shares Expires 2030-02-05 F2 · kind: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. F2 · derivative.exercise_date: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 2,222 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020004 · form4-07242024_120741.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,181 F3 · shares: These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on January 19, 2026 and one-twelfth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 20:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 33,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-020004 · form4-07242024_120741.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,959 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-half of the RSUs shall vest on July 19, 2025 and one-eighth of the RSUs shall vest each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. F2 · price: Pursuant to the Issuer's previously disclosed option exchange program, on July 19, 2024 the Issuer cancelled the Reporting Person's options to purchase 55,000 shares and 40,000 shares of the Issuer's Common Stock and in exchange issued aggregate RSU grants of 33,111 shares and 2,222 shares. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 19:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,570 | $7.58 | $11,893.22 |
DisclosureSEC source: 0001415889-24-017499 · form4-06182024_110617.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,848 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.26 to $7.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 19:53 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 2,543 | $10.17 | $25,863.58 |
DisclosureSEC source: 0001415889-24-008169 · form4-03152024_110314.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,418 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $9.80 to $10.43. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 19:53 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 2,897 | $9.88 | $28,608.45 |
DisclosureSEC source: 0001415889-24-008169 · form4-03152024_110314.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,961 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.625 to $10.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:22 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001415889-24-008054 · form4-03142024_100336.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2034-03-12 F2 · derivative.exercise_date: One forty-eighth of the shares subject to the option shall vest on April 12, 2024 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 18:22 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 46,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008054 · form4-03142024_100336.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,858 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-sixteenth of the RSUs shall vest on June 12, 2024 and each three-month anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 20:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,337 | $5.06 | $6,764.15 |
DisclosureSEC source: 0001209191-23-056944 · doc4.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,608 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.96 to $5.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 15, 2023 Filed Nov 29, 2023 20:49 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 234 | $11.71 | $2,740.14 |
DisclosureSEC source: 0001209191-23-056944 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,945 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 23, 2023 Filed May 25, 2023 19:23 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 15 | $13.01 | $195.08 |
DisclosureSEC source: 0001209191-23-032305 · doc4.xml · nonDerivative · entry 3 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,711 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.02. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 23, 2023 Filed May 25, 2023 19:23 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,244 | $12.30 | $15,301.82 |
DisclosureSEC source: 0001209191-23-032305 · doc4.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,726 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $12.00 to $12.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 15, 2023 Filed May 25, 2023 19:23 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 398 | $11.71 | $4,660.58 |
DisclosureSEC source: 0001209191-23-032305 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,970 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:45 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001209191-23-023702 · doc4.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2033-04-04 F2 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest on April 12, 2023 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 21:45 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023702 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,572 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2024 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 14, 2023 Filed Mar 16, 2023 18:30 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,768 | $18.73 | $33,118.18 |
DisclosureSEC source: 0001209191-23-019420 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,322 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.34 to $19.30. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 19, 2022 Filed Dec 20, 2022 20:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 3,801 | $20.00 | $76,020.00 |
DisclosureSEC source: 0001209191-22-062260 · doc4.xml · nonDerivative · entry 3 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,090 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 20:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 815 | $19.36 | $15,777.99 |
DisclosureSEC source: 0001209191-22-062260 · doc4.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,891 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.30 to $19.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 20:09 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 1,468 | $18.77 | $27,561.11 |
DisclosureSEC source: 0001209191-22-062260 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,706 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.29 to $19.289. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 20:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 277 | $21.99 | $6,091.62 |
DisclosureSEC source: 0001209191-22-058912 · doc4.xml · nonDerivative · entry 3 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,174 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F4 · price: This transaction was executed in multiple trades at prices ranging from $21.74 to $22.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 20:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 600 | $21.38 | $12,825.90 |
DisclosureSEC source: 0001209191-22-058912 · doc4.xml · nonDerivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,451 F2 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.74 to $21.73. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| November 15, 2022 Filed Nov 28, 2022 20:31 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 353 | $12.84 | $4,532.52 |
DisclosureSEC source: 0001209191-22-058912 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,051 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 26, 2022 Filed May 26, 2022 16:48 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | SaleCommon Stock | 950 | $17.10 | $16,247.47 |
DisclosureSEC source: 0001209191-22-032232 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,698 F1 · kind: These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.8061 to $17.1269. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 13, 2022 Filed May 17, 2022 19:00 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 391 | $12.38 | $4,840.58 |
DisclosureSEC source: 0001209191-22-029859 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,648 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 18:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 6,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-019760 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,257 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs shall vest in December 2022, provided that the Reporting Person remains a service provider through the vesting date. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:54 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-22-019013 · doc4.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2032-03-12 F2 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest on April 12, 2022 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| March 12, 2022 Filed Mar 15, 2022 20:54 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-019013 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,173 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2023 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 18:50 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 86 | $50.99 | $4,385.14 |
DisclosureSEC source: 0001209191-21-065259 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,673 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2021 Filed Nov 19, 2021 20:36 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065986 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,673 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs will vest on each of May 23, 2022, November 22, 2022, May 22, 2023, and November 22, 2023, provided that the Reporting Person remains a service provider through each vesting date. Read SEC document |
| May 14, 2021 Filed May 18, 2021 21:42 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 45 | $45.90 | $2,065.50 |
DisclosureSEC source: 0001209191-21-033861 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 19:18 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Exercise / conversionStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-21-019267 · doc4.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,097 Underlying: Common Stock · 2,750 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 125,597 shares, of which 5,500 shares have been exercised, vested as to 1/4 of the shares on January 1, 2020, and an additional 1/48 of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person remaining a service provider through each such date. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 19:18 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Exercise / conversionCommon Stock | 2,750 | $1.39 | $3,822.50 |
DisclosureSEC source: 0001209191-21-019267 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 21:35 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $91.50 | $0.00 |
DisclosureSEC source: 0001209191-21-013593 · doc4.xml · derivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-19 F1 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest each month following February 19, 2021 on the same day of the month, subject to Reporting Person remaining a service provider through each such date. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Exercise / conversionStock Option (right to buy) · Derivative | 2,750 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-20-064850 · doc4.xml · derivative · entry 2 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,847 Underlying: Common Stock · 2,750 shares Expires 2029-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally for 125,597 shares, of which 2,750 shares have been exercised, vested as to 1/4 of the shares on January 1, 2020, and an additional 1/48 of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person remaining a service provider through each such date. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 16:43 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | Exercise / conversionCommon Stock | 2,750 | $1.39 | $3,822.50 |
DisclosureSEC source: 0001209191-20-064850 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 20:51 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantCommon Stock | 42 | $45.45 | $1,908.90 |
DisclosureSEC source: 0001209191-20-058934 · doc4.xml · nonDerivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42 F1 · kind: The shares were acquired under the IGM Biosciences, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 17:50 UTC | IGM Biosciences, Inc. IGMS · Entity 76422 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $40.27 | $0.00 |
DisclosureSEC source: 0001209191-20-007632 · doc4.xml · derivative · entry 1 Tahir Misbah · CIK 0001787359 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-02-05 F1 · derivative.exercise_date: 1/48 of the shares subject to the option shall vest each month following February 5, 2020 on the same day of the month subject to Reporting Person remaining a service provider through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.